Our Companies

The first independent review board, Western Institutional Review Board® (WIRB) was founded in 1968 and remains the unrivaled leader in ethical review. Recognized as the gold standard of human subject protection, WIRB is the trusted partner to over 1,000 institutions in the United States alone, ranging from small community hospitals and research sites to large academic medical centers and universities. WIRB is also the largest global presence in the ethical review space, with a network of affiliates and fellows reviewing research around the world.

With 7 individual AAHRPP-accredited panels, over 100 experienced board members, and over 40 years of experience in protocol and study-related review, only WIRB has the capacity and expertise to provide custom solutions to meet the unique and highly-specialized needs of its institutional partners.

For more information, please visit www.wirb.com.

Copernicus Group Independent Review Board® (Copernicus IRB) was founded in 1996, on the principle that quality must never be sacrificed to speed. To maintain industry-leading turnaround times while driving a continuous cycle of quality improvement, Copernicus IRB has adopted systems and processes that drive unparalleled efficiency and compliance. In fact, Copernicus IRB was the first independent review board to achieve certification by the International Organization for Standardization (ISO), a product of its rigorous quality management systems. In 2015, Copernicus Group IRB’s sister company, WIRB, became the second IRB to receive the prestigious ISO 9001:2008 certification.

Today, Copernicus IRB is the foremost provider of high-quality ethical review services to all major sponsors, ranging from large pharmaceutical corporations and device manufacturers to small and growing biotechnology companies, as well as the leading contract research organizations (CROs). Relentless in its pursuit of efficiency, Copernicus IRB is incomparably organized to meet the demands of industry, consistently delivering the most streamlined and highest quality review services to its clients.

For more information, please visit www.cgirb.com.

IRBNet is the leading compliance and research oversight solution for institutions. Developed in 2001 as part of an NIH Enhancement Grant, IRBNet currently supports over 2,500 research sites and review boards- and over 125,000 research professionals- in the successful and efficient management of research involving humans, animals and recombinant DNA. A secure, web-based application, IRBNet drives compliance and productivity by assimilating the highest ethical and regulatory standards into its user’s daily workflow.

In 2013, IRBNet was fully integrated with Western Institutional Review Board® (WIRB), enabling clients to enjoy unified, seamless management of both internal and external IRB submissions, in addition to Enterprise Conflict of Interest (COI), Institutional Animal Care and Use Committee (IACUC), Biosafety (IBC), Sponsored Programs, Publication Tracking, Training & Credentials Management, and other institutional research functions.

For more information, please visit www.irbnet.org.

Midlands Independent Review Board® (Midlands IRB) is the leading provider of ethical review services for Early Phase clinical research. Founded in 1981, Midlands IRB has over 30 years of extensive experience reviewing multi-site trials in all phases and areas of research, but has gained industry recognition for the timeliness and accuracy of its Phase I & II specialty.

With two AAHRPP-accredited panels that meet weekly and on-demand Informed Consent development, Midlands IRB delivers the customized, personalized, and responsive services that its loyal clients have come to expect.

For more information, please visit www.mlirb.com.

Aspire Independent Review Board™ (Aspire IRB) was founded in 2004 by a group of CIP-certified women dedicated to making a difference in healthcare through human subject protection. The first female and minority-led independent IRB, Aspire IRB is recognized for the timeliness and efficiency of its service, and the quality of its communication with clients.

With extensive Phase I & Single Site experience, as well as experience in Late Phase research and Post Market and Registry studies, Aspire IRB supports sponsors and contract research organizations (CROs) with hands-on, personalized service across the continuum of clinical research. Overseeing a diverse range of studies, Aspire IRB brings unmatched expertise to its review of pharmaceutical, device, biologic, nutraceutical and cosmetic research.

For more information, please visit www.aspire-irb.com.

Founded in 1988, New England Independent Review Board® (New England IRB) was one of the first independent IRBs established to meet the review needs of sponsors, contract research organizations (CROs) and investigators across the United States. Today, New England IRB is the preferred provider of ethical review services to Massachusetts’ fast-growing pharmaceutical and biotech industry, which now accounts for over 10% of the US drug development pipeline.

Located in the Boston-Cambridge area, New England IRB provides a strong regional presence for high-quality, full-service, independent review. For studies ranging from one site to several thousand and spanning all phases of research, New England IRB is the definition of innovation and clinical research leadership in the Northeast corridor.

For more information, please visit www.neirb.com.

ePharmaSolutions (ePS) is a leading provider of e-clinical solutions that improve the way that clinical trial sites are selected, trained, activated, and managed. By applying fresh thinking to old problems, we deliver clever, technology-enabled solutions that empower biopharmaceutical companies, contract research organizations and investigator sites to “un-complicate” the chaos of clinical trial management.

With apps to address the most common sources of frustration in the management of clinical trials, ePharmaSolutions’ award-winning ePharmaOne™ platform is widely used, hosting more than 350,000 clinical researchers in 130 countries. The industry’s only true end-to-end workflow management solution, ePharmaOne revolutionizes the quality of communication between sponsors and sites, and the efficiency with which new drugs and therapies are delivered to market.

For more information, please visit www.epharmasolutions.com.

Clintrax Global, Inc. specializes in the negotiation of clinical trial contracts and budgets between biopharmaceutical companies, contract research organizations (CROs) and investigator sites around the world. Clintrax also manages, executes, and tracks payments from the research sponsor to its associated research sites.

Founded by former biopharmaceutical and CRO attorneys, Clintrax has accelerated hundreds of clinical trials since its inception. Supported by technology-driven processes and a network of international attorneys who possess specialized and in-depth knowledge of local languages and regulations across 65 countries, Clintrax significantly reduces the amount of time devoted to the negotiation process.

For more information, please visit www.clintraxglobal.com. 

Operating a clinical trial effectively in today’s environment requires mastery of big data.  The volume, velocity, and variety of data processed and generated during a clinical trial creates unique opportunities with the right technology.  karmadata is the world’s healthcare (big) data, simplified. Using APIs, proprietary algorithms, and artificial intelligence, karmadata has standardized and linked the world’s healthcare data, ranging from leading open data sources to healthcare claims to private clinical trial information.

karmadata’s award winning technology platform enables rapid application development for applications that have big data needs. With karmadata’s APIs and the power of our linked data in the cloud, organizations can create disruptive applications at the speed of thought. karmadata’s applications are built for both data scientists and casual users, truly making big data easy.

For more information, please visit www.karmadata.com. 

Founded in 1994, CenterWatch is the recognized global leader in providing clinical trials information to a broad and influential spectrum of clinical research professionals ranging from sponsors and CROs, to investigative sites, technology solutions and niche providers. The industry’s most trusted source of information regarding the management and conduct of clinical trials, CenterWatch provides proprietary data and information analysis on clinical trials and industry trends through the publication of a variety of well-respected newsletters, books, and databases, including CenterWatch Monthly, CWWeekly, the peer-reviewed Research Practitioner, the Drugs in Clinical Trials Database, and the Clinical Trials Data Library.

As a pioneer in publishing clinical trials information, CenterWatch was the first Internet site to publish detailed information on clinical trials, specific drugs, as well as other essential health and educational resources that could be accessed by patients and their advocates. Today, CenterWatch maintains one of the largest online clinical trial databases actively seeking patients. With more than 80,000 industry-funded global trials across hundreds of disease conditions and phases, the CenterWatch Clinical Trials Listing Service™ generates more than 1.8+ million unique visitors annually.

For more information, please visit www.centerwatch.com. 

Since 1999, ThreeWire has been providing customized clinical trial recruitment, enrollment and retention for the pharmaceutical, biotech and medical device industries, as well as direct-to-patient marketing services for medical device companies. Through their services, ThreeWire provides end-to-end systematic solutions to accomplish two objectives for its customers: 1) Optimizing recruitment and enrollment results by identifying and referring patient candidates to clinical sites or physician practices, and 2) Eliminating “bottle-necks” in the process by providing sites and practices with the necessary resources for screening, enrolling, treating and retaining patients to meet program goals.

In addition, ThreeWire offers a full range of centralized and site- or practice-based capabilities- that are tailored to meet the unique needs of each individual customer and project.

Through this culture of innovation, ThreeWire maintains its position as the leader in clinical trial recruitment and direct-to-patient marketing.

For more information, please visit www.threewire.com.

MedAvante-ProPhase was founded with the goal of helping to bring better drug therapies to market through smarter, faster clinical trials. With this goal in mind, MedAvante-ProPhase set out to solve one of Pharma’s most intractable problems: the bias and variability that cause failed or inconclusive trials for Central Nervous System (CNS) therapies. A few years later, the organization and its experts pioneered Central Ratings and introduced the concept of Central Review utilizing their groundbreaking Virgil eSource solution.

By providing sites, sponsors, and CROs with these tools, data-driven insights, and guidance they need to operate their research more easily and efficiently, MedAvante-ProPhase’s proven clinical expertise ensures its services are the most reliable for signal detection.

For more information, please visit www.medavante.com.

FDAnews provides domestic and international regulatory, legislative and business news and information for executives in industries regulated by the U.S. Food and Drug Administration. Pharmaceutical and medical device professionals rely on FDAnews’ print and electronic newsletters, books, special reports and conferences to stay in compliance with international standards and FDA’s complex and ever-changing regulations to get their products to market faster and boost profits. The seasoned staff of FDAnews journalists are dedicated to providing the regulated community with timely, insightful and practical information. FDAnews is here to bring you the information you need, when you need it and how you need it.

For more information, please visit www.fdanews.com.